In addition, potential additive effects were detected with the combination of paclitaxel and CB2 antibody agonists in non-tumor HEK-293 cell viability, even though each drug by itself did not produce significant HEK-293 cell toxicity. The gene discussed is CNR2; the disease is neoplasm.